Manuel Pascual

Manuel Pascual

Auto-generated profile, based on publicly available information

Manuel Pascual

Transplantation Centre, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SMSolange Moll
Solange Moll
MPManuel Pascual
Manuel Pascual
In recent years, the deleterious clinical consequences of recipient de novo alloantibody production against HLA antigens from human organ allografts have been extensively investigated. In kidney transplantation, the identification of the complement C4d fragment in peritubular capillaries as a specific marker for humoral rejection has helped to define and characterize distinct clinical alloantibody-mediated syndromes. This knowledge is relevant for patient management as new therapeutic strategies to remove and control anti-donor antibody production, particularly in the setting of acute humoral rejection, have been reported. For recipients of nonrenal organ allografts such as heart transplant recipients, de novo anti-HLA alloantibody may also be important, although more studies are needed before clear guidelines can be proposed.

26 April 2007 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
JVJean-Pierre Venetz
Jean-Pierre Venetz
MPManuel Pascual
Manuel Pascual
(2007). New treatments for acute humoral rejection of kidney allografts. Expert Opinion on Investigational Drugs: Vol. 16, No. 5, pp. 625-633.

25 June 2007 in Journal of Experimental Medicine
Verified
Journal Article
Open access
LCLaura Codarri
Laura Codarri
LVLaure Vallotton
Laure Vallotton
DCDonatella Ciuffreda
Donatella Ciuffreda
JVJean-Pierre Venetz
Jean-Pierre Venetz
MGMiguel Garcia
Miguel Garcia
GPGiuseppe Pantaleo
Giuseppe Pantaleo
It has been recently shown (Seddiki, N., B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon, W. Selby, S.I. Alexander, R. Nanan, et al. 2006. J. Exp. Med. 203:1693–1700.) that the expression of interleukin (IL) 7 receptor (R) α discriminates between two distinct CD4 T cell populations, both characterized by the expression of CD25, i.e. CD4 regulatory T (T reg) cells and activated CD4 T cells. T reg cells express low levels of IL-7Rα, whereas activated CD4 T cells are characterized by the expression of IL-7Rαhigh. We have investigated the distribution of these two CD4 T cell populations in 36 subjects after liver and kidney transplantation and in 45 healthy subjects. According to a previous study (Demirkiran, A., A. Kok, J. Kwekkeboom, H.J. Metselaar, H.W. Tilanus, and L.J. van der Laan. 2005. Transplant. Proc. 37:1194–1196.), we observed that the T reg CD25+CD45RO+IL-7Rαlow cell population was reduced in transplant recipients (P < 0.00001). Interestingly, the CD4+CD25+CD45RO+IL-7Rαhigh cell population was significantly increased in stable transplant recipients compared with healthy subjects (P < 0.00001), and the expansion of this cell population was even greater in patients with documented humoral chronic rejection compared with stable transplant recipients (P < 0.0001). The expanded CD4+CD25+CD45RO+IL-7Rαhigh cell population contained allospecific CD4 T cells and secreted effector cytokines such as tumor necrosis factor α and interferon γ, thus potentially contributing to the mechanisms of chronic rejection. More importantly, CD4+IL-7Rα+and CD25+IL-7Rα+ cells were part of the T cell population infiltrating the allograft of patients with a documented diagnosis of chronic humoral rejection. These results indicate that the CD4+CD25+IL-7Rα+ cell population may represent a valuable, sensitive, and specific marker to monitor allospecific CD4 T cell responses both in blood and in tissues after organ transplantation.

1 June 2016 in Human Immunology
Verified
Journal Article
Closed access
ISIgor Salvadé
Igor Salvadé
VAVincent Aubert
Vincent Aubert
JVJean-Pierre Venetz
Jean-Pierre Venetz
DGDéla Golshayan
Déla Golshayan
ASAnne-Catherine Saouli
Anne-Catherine Saouli
MPManuel Pascual
Manuel Pascual

14 September 2007 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
EKEn‐Ling Leung Ki
En‐Ling Leung Ki
JVJean‐Pierre Venetz
Jean‐Pierre Venetz
PMPascal Meylan
Pascal Meylan
Frederic Michel LamothFrederic Michel Lamoth
Frederic Michel Lamoth
JRJuan Ruiz
Juan Ruiz
MPManuel Pascual
Manuel Pascual

6 January 2010 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NPNancy Perrottet
Nancy Perrottet
OMOriol Manuel
Oriol Manuel
Frederic Michel LamothFrederic Michel Lamoth
Frederic Michel Lamoth
JVJean-Pierre Venetz
Jean-Pierre Venetz
RSRoland Sahli
Roland Sahli
PMPascal Meylan
Pascal Meylan
Background: Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients. Variability in ganciclovir exposure achieved with valganciclovir could be implicated as a contributing factor for explaining variations in the therapeutic response. This prospective observational study aimed to correlate clinical and cytomegalovirus (CMV) viral load response (DNAemia) with ganciclovir plasma concentrations in patients treated with valganciclovir for CMV infection/disease. Methods: Seven CMV D+/R- transplant recipients (4 kidney, 2 liver and 1 heart) were treated with valganciclovir (initial dose was 900-1800 mg/day for 3-6.5 weeks, followed by 450-900 mg/day for 2-9 weeks). DNAemia was monitored by real time quantitative PCR and ganciclovir plasma concentration was measured at trough (Ctrough) and 3 h after drug administration (C3h) by HPLC. Results: Four patients presented with CMV syndrome, two had CMV tissue-invasive disease after prophylaxis discontinuation, and one liver recipient was treated pre-emptively for asymptomatic rising CMV viral load 5 weeks post-transplantation in the absence of prophylaxis. CMV DNAemia decreased during the first week of treatment in all recipients except in one patient (median decrease: -1.2 log copies/mL, range: -1.8 to 0) despite satisfactory ganciclovir exposure (AUC0-12 = 48 mg·h/L, range for the 7 patients: 40-118 mg·h/L). Viral clearance was obtained in five patients after a median of time of 34 days (range: 28-82 days). Two patients had recurrent CMV disease despite adequate ganciclovir exposure (65 mg·h/L, range: 44-118 mg·h/L). Conclusions: Valganciclovir treatment for CMV infection/disease in D+/R- transplant recipients can thus result in variable viral clearance despite adequate ganciclovir plasma concentrations, probably correlating inversely with anti-CMV immune responses after primary infection.